Floatz logo

Rifaximin

Pathological Processes

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Small moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Pathological Processes cohort.

Asset / SponsorPhaseRating
LACTULOSE
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 4BB

Same molecule, other indications

Rifaximin is also rated in:

hepatic encephalopathyDormant
BBB
Indicative ·
75 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →
AscitesDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →